Chardan Raises Price Target on ProQR Therapeutics
November 8, 2024
Senior research analyst, Keay Nakae, is featured on NASDAQ for raising ProQR's price target to $4 while maintaining a Buy rating following the company's Q3 report.
NASDAQ | Read more ›
Thank You!
We've received your information, and we're processing your request.
Get In Touch.
All fields required